Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting
CA 2176014 A1 · Owner: The Wellcome Foundation Limited · Inventors: Richards, Cynthia Ann; Huber, Brian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the transcriptional regulatory sequence (TRS) of carcinoembryonic antigen (CEA) and molecular chimaera comprising the CEA TRS and DNA encoding a heterologous enzyme. CEA TRS is capable of targeting expression of the heterologous enzyme to CEA+ cells and the heterologous enzyme is preferably an enzyme capable of catalysing the production of an agent cytotoxic or cytostatic to CEA+ cells. For example the enzyme may be cytosine deaminase which is capable of catalysing formation of the cytotoxic compound 5-fluorouracil from the non toxic compound 5-fluorocytosine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 18, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 18, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 18, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.